Confidence in Generic Drug Substitution
Authors:
- 1 October 2013
- journal article
- editorial
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 94 (4) , 438-440
Abstract
Patients should have confidence that the generic drugs they are prescribed in the United States can be effectively substituted for the brand product or another generic product. Through new bioequivalence study designs for narrow therapeutic index (NTI) drugs and postapproval studies of generic substitution, the US Food and Drug Administration's (FDA's) ongoing generic drug regulatory science activities are designed to ensure successful generic substitution for all drug products. Clinical Pharmacology & Therapeutics (2013); 94 4, 438–440. doi:10.1038/clpt.2013.104Keywords
This publication has 5 references indexed in Scilit:
- Interchangeability of Gabapentin Generic Formulations in the Netherlands: A Comparative Bioavailability StudyClinical Pharmacology & Therapeutics, 2013
- Interchangeability of generic anti-epileptic drugs: a quantitative analysis of topiramate and gabapentinEuropean Journal of Clinical Pharmacology, 2011
- State Generic Substitution Laws Can Lower Drug Outlays Under MedicaidHealth Affairs, 2010
- Comparing Generic and Innovator Drugs: A Review of 12 Years of Bioequivalence Data from the United States Food and Drug AdministrationAnnals of Pharmacotherapy, 2009
- Acetaminophen metabolism in subjects fed charcoal-broiled beefClinical Pharmacology & Therapeutics, 1983